Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R GARZON

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Leukemia|June 10, 2015
Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemiaA M Dorrance, P Neviani, G J Ferenchak, et al.
Leukemia|June 22, 2016
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignanciesZ A Hing, H Y J Fung, P Ranganathan, et al.
Leukemia|November 27, 2012
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemiaA Mims, A R Walker, X Huang, et al.
Leukemia|May 15, 2015
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemiaJ Khalife, H S Radomska, R Santhanam, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Leukemia|June 10, 2015
Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemiaA M Dorrance, P Neviani, G J Ferenchak, et al.
Leukemia|June 22, 2016
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignanciesZ A Hing, H Y J Fung, P Ranganathan, et al.
Leukemia|November 27, 2012
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemiaA Mims, A R Walker, X Huang, et al.
Leukemia|May 15, 2015
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemiaJ Khalife, H S Radomska, R Santhanam, et al.
Pageof 2